Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,388 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,388 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT07100925 | A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk… | Phase 1 | withdrawn | Aug 3, 2025 | Ankyra Therapeutics, Inc | Strategic realignment | Sponsor / business decision |
| NCT07136493 | Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With… | N/A | withdrawn | Aug 22, 2025 | City of Hope Medical Center | Funding This study has been closed at City of Hope at the request of the Sponsor due to delays and… | Funding |
| NCT01012297 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients… | Phase 3 | terminated | Nov 13, 2009 | National Cancer Institute (NCI) | The study was targeted to accrue 130 patients, but closed early for futility. | Efficacy / futility |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation(NIVOLEP) | Phase 2 | terminated | Aug 15, 2018 | Assistance Publique - Hôpitaux de Paris | Because patient recruitment was affected by the COVID-19 pandemic, the study sponsor and funding… | COVID-19 / pandemic |
| NCT05416554 | Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received… | N/A | withdrawn | Jun 13, 2022 | Stanford University | No participants enrolled | Enrollment / accrual |
| NCT06692959 | A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal…(Neo-POLEM) | Phase 2 | terminated | Nov 18, 2024 | University of Southampton | funding withdrawal | Funding |
| NCT00520975 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses… | Phase 3 | terminated | Aug 27, 2007 | National Cancer Institute (NCI) | Closed early due to slow accrual | Enrollment / accrual |
| NCT03353428 | Intervention of Engineered Immune Effector T Cells Against Lung Cancer | Phase 1 / Phase 2 | withdrawn | Nov 27, 2017 | Shenzhen Geno-Immune Medical Institute | combine with NCT03356808 | Other (stated, no rule matched) |
| NCT04346225 | Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in… | Phase 2 | suspended | Apr 15, 2020 | Ivan de Kouchkovsky, MD | Due to funding | Funding |
| NCT04734704 | Defining the Role of the Skin Microbiome in Immune-related Adverse Events(SKINBIOTA) | N/A | terminated | Feb 2, 2021 | University Hospital, Bordeaux | target number of patients not reached and disabling team changes | Other (stated, no rule matched) |
| NCT04581109 | Detection of Viable CTCs Using the EPIDROP Technology in Metastatic Prostate Cancer…(EPIDROP) | N/A | terminated | Oct 9, 2020 | University Hospital, Montpellier | Flaw in the analytical technique | Other (stated, no rule matched) |
| NCT05025514 | Retrospective Study of COVID-19 Vaccines in Patients Undergoing Immunotherapy for Cancer.(IVACOV) | — | terminated | Aug 27, 2021 | Centre Hospitalier Universitaire de Nīmes | end of the COVID outbreak | COVID-19 / pandemic |
| NCT05315011 | Assessment of Cryotherapy's Analgesic Impact in Anti-aromatase-induced Arthralgia(CRYOMATASE) | N/A | suspended | Apr 7, 2022 | University Hospital, Montpellier | The cryotherapy center has closed due to liquidation. | Other (stated, no rule matched) |
| NCT05350527 | Impact of Video Information Support on Preoperative Anxiety in Breast Cancer Surgery(SENEDOP) | N/A | terminated | Apr 28, 2022 | University Hospital, Montpellier | The software used for the collection of the primary endpoint is no longer available. | Other (stated, no rule matched) |
| NCT07216833 | Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell… | Phase 1 | withdrawn | Oct 15, 2025 | Case Comprehensive Cancer Center | PI leaving the institution | Other (stated, no rule matched) |
| NCT07524257 | Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care… | Phase 3 | withdrawn | Apr 13, 2026 | ImmunityBio, Inc. | Sponsor decision | Sponsor / business decision |
| NCT07570966 | Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients… | Phase 1 / Phase 2 | withdrawn | May 6, 2026 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT00253318 | RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer | Phase 1 | terminated | Nov 15, 2005 | M.D. Anderson Cancer Center | Toxicity and Lack of Efficacy | Safety / toxicity |
| NCT02389985 | A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With… | Phase 1 / Phase 2 | terminated | Mar 17, 2015 | NewLink Genetics Corporation | Company decision | Sponsor / business decision |
| NCT04702854 | Evaluation of Ultrasound Biomicroscopy in the Local Staging of Cutaneous Melanoma(BMUMM) | N/A | terminated | Jan 11, 2021 | Centre Hospitalier Universitaire de Nice | recruitment challenges | Enrollment / accrual |
| NCT04975516 | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for… | Phase 2 | terminated | Jul 23, 2021 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT05130255 | GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | terminated | Nov 23, 2021 | Y-mAbs Therapeutics | Decision by Sponsor | Other (stated, no rule matched) |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | terminated | Aug 24, 2022 | Day One Biopharmaceuticals, Inc. | Development discontinued. | Other (stated, no rule matched) |
| NCT05537402 | LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC(LOST-B) | Phase 2 | terminated | Sep 13, 2022 | University of Texas Southwestern Medical Center | The decision was made to close the study to enrollment due to poor overall accrual and the… | Enrollment / accrual |
| NCT06274437 | A Study of BND-35 in Participants With Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2024 | Biond Biologics | Study terminated due to strategic considerations | Sponsor / business decision |
| NCT07428369 | A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly…(LINKER-MM8) | Phase 2 / Phase 3 | withdrawn | Feb 23, 2026 | Regeneron Pharmaceuticals | Sponsor Decision | Sponsor / business decision |
| NCT01272609 | Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel | Phase 3 | terminated | Jan 10, 2011 | Centre Hospitalier Universitaire de Nice | Rupture du traitement | Other (stated, no rule matched) |
| NCT02626312 | Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma,… | Phase 1 | terminated | Dec 10, 2015 | M.D. Anderson Cancer Center | \< 75% participation | Other (stated, no rule matched) |
| NCT03631199 | Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy…(CANOPY-1) | Phase 3 | terminated | Aug 15, 2018 | Novartis Pharmaceuticals | Results of primary analysis showed addition of canakinumab to combination treatment did not improve… | Safety / toxicity |
| NCT02903277 | National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With… | — | withdrawn | Sep 16, 2016 | Centre Hospitalier Universitaire de Nice | L'investigateur est parti du CHU de Nice | Other (stated, no rule matched) |
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple… | Phase 1 | terminated | Aug 12, 2022 | Second Affiliated Hospital of Xi'an Jiaotong University | Achieved the proof of concept | Other (stated, no rule matched) |
| NCT05789589 | Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain…(ADORATION) | Phase 1 / Phase 2 | suspended | Mar 29, 2023 | Baptist Health South Florida | Funding | Funding |
| NCT07136571 | Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable… | N/A | withdrawn | Aug 22, 2025 | University of Alabama at Birmingham | Study PI is leaving UAB and no longer opening study. | Other (stated, no rule matched) |
| NCT03879629 | Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to… | Phase 2 | terminated | Mar 19, 2019 | Mayo Clinic | slow accrual; insufficient funding to continue to accrue | Enrollment / accrual |
| NCT04158635 | Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic… | Phase 1 | suspended | Nov 12, 2019 | City of Hope Medical Center | Accrual Goal met | Enrollment / accrual |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With… | Phase 2 / Phase 3 | terminated | Jan 6, 2021 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT05414500 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | Phase 1 | suspended | Jun 10, 2022 | University of Alabama at Birmingham | IRB audit | Other (stated, no rule matched) |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | Phase 2 | terminated | Jul 12, 2022 | University of Washington | The trial closed early due to slow accrual. | Enrollment / accrual |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | Phase 2 / Phase 3 | terminated | Oct 28, 2022 | Wake Forest University Health Sciences | Study initially suspended following an audit and need of amendment to address deficiencies. PI… | Other (stated, no rule matched) |
| NCT06902246 | Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | withdrawn | Mar 30, 2025 | University of Miami | Investigator decision | Investigator |
| NCT01148056 | Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer | N/A | terminated | Jun 22, 2010 | Massachusetts General Hospital | The study was closed to enrollment due to slow accrual. | Enrollment / accrual |
| NCT02602756 | Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas(HYGROMEL) | N/A | terminated | Nov 11, 2015 | Centre Antoine Lacassagne | insufficient quality of data collection | Other (stated, no rule matched) |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20… | Phase 2 | terminated | Oct 24, 2017 | Spectrum Pharmaceuticals, Inc | Strategic business decision (unrelated to safety) | Safety / toxicity |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | Phase 2 | terminated | Sep 22, 2022 | Sun Yat-sen University | The study was terminated due to initiation of a new clinical trial with an updated study design. | Other (stated, no rule matched) |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the… | Phase 2 | terminated | Oct 13, 2022 | Northwestern University | The study was closed due to accrual. | Enrollment / accrual |
| NCT02409316 | [18F]FES PET/CT in Endocrine Refractory Breast Cancer | Phase 2 | terminated | Apr 6, 2015 | University of Pennsylvania | not stated | Not stated |
| NCT03866109 | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT(TEM-GBM) | Phase 1 / Phase 2 | terminated | Mar 7, 2019 | Genenta Science | LVLP (pt GBM-01034) took place on 27may2026. The 2 remaining slots allocated by the protocol for… | Safety / toxicity |
| NCT04745871 | Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in…(PREOP-PSMA) | N/A | terminated | Feb 9, 2021 | University Hospital, Brest | In the PREOP-PSMA protocol, written before 68Ga-PSMA-11 obtained Marketing Authorization. Today,… | Other (stated, no rule matched) |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally… | Phase 2 | terminated | Aug 2, 2021 | NeoImmuneTech | sponsor decision (not for safety) | Safety / toxicity |
| NCT05744739 | Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) | Phase 1 | terminated | Feb 27, 2023 | Northwestern University | Premature withdrawal of investigational product per study sponsor. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials